Latest & greatest articles for lansoprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lansoprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lansoprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lansoprazole

1. Lansoprazole

Lansoprazole Top results for lansoprazole - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lansoprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

2. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study 28988197 2017 10 08 2017 10 08 1468-3288 2017 Oct 07 Gut Gut Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. gutjnl-2017-314010 10.1136/gutjnl-2017-314010 To assess the non-inferiority of vonoprazan to lansoprazole for secondary (...) prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use. A phase 3, 24-week, multicenter, randomised, double-blind (DB), active-controlled study, followed by a phase 3, ≥28 week, multicenter, single-blind, parallel-group extension study (EXT) in outpatients (n=642) receiving long-term NSAID therapy who are at risk of PU recurrence. The patients received vonoprazan (10 mg or 20 mg) or lansoprazole 15 mg once daily. For DB, non

EvidenceUpdates2017

3. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy

Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy 26338726 2015 10 09 2016 01 15 2015 10 09 1468-3288 64 11 2015 Nov Gut Gut Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. 1715-20 10.1136/gutjnl-2015-309900 To evaluate the efficacy and tolerability of replacing tetracycline with amoxicillin in bismuth quadruple therapy. Subjects who were infected with Helicobacter (...) pylori and naïve to treatment were randomly (1:1) assigned to receive a 14-day modified bismuth quadruple therapy: lansoprazole 30 mg, amoxicillin 1 g, bismuth potassium citrate 220 mg (elemental bismuth), twice a day with metronidazole 400 mg four times a day (metronidazole group) or clarithromycin 500 mg twice a day (clarithromycin group). Six weeks after treatment, H. pylori eradication was assessed by 13C-urea breath test. Antimicrobial susceptibility was assessed by the twofold agar dilution

EvidenceUpdates2015

4. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.

Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. 22274684 2012 01 25 2012 01 26 2016 12 15 1538-3598 307 4 2012 Jan 25 JAMA JAMA Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. 373-81 10.1001/jama.2011.2035 Asymptomatic gastroesophageal reflux (GER) is prevalent in children with asthma. Untreated GER has been postulated to be a cause of inadequate asthma control in children despite inhaled corticosteroid treatment (...) , but it is not known whether treatment with proton pump inhibitors improves asthma control. To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER. The Study of Acid Reflux in Children With Asthma, a randomized, masked, placebo-controlled, parallel clinical trial that compared lansoprazole with placebo in children with poor asthma control who were receiving inhaled corticosteroid treatment. Three hundred six participants enrolled from April 2007

JAMA2012 Full Text: Link to full Text with Trip Pro

5. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients

A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients 19515110 2009 08 17 2009 09 15 2013 11 21 1532-5415 57 8 2009 Aug Journal of the American Geriatrics Society J Am Geriatr Soc A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. 1453-7 10.1111/j.1532-5415.2009.02349.x To investigate whether proton pump inhibitor (...) with gastroesophageal reflux disease or gastroduodenal ulcer were excluded. Patients were randomly assigned to conventional therapies (control group) or conventional therapies plus PPI (lansoprazole 15 mg/d; PPI group) and observed for 12 months. Frequency of common colds and COPD exacerbations. The number of exacerbations per person in a year in the PPI group was significantly lower than that in the control group (0.34 +/- 0.72 vs 1.18 +/- 1.40; P<.001). The adjusted odds ratio with logistic regression for having

EvidenceUpdates2009

6. Lansoprazole oro-dispersible tablet (Zoton FasTab)

Lansoprazole oro-dispersible tablet (Zoton FasTab) Scottish Medicines Consortium Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: Rosie.Murray@nhshealthquality.org Chairman Professor David Webb Lansoprazole oro-dispersible tablet 15 mg, 30 mg (Zoton FasTab) (No: 229/05) Wyeth Product Update 9 December 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic (...) Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission Lansoprazole oro-dispersible tablet (Zoton FasTabÒ) is accepted for use in NHS Scotland, in combination with appropriate antibiotics, for the eradication of Helicobacter pylori from the upper gastrointestinal tract in patients with ulcer-like dyspepsia in whom Helicobacter pylori infection has been demonstrated. The standard formulation of lansoprazole also has this indication

Scottish Medicines Consortium2006

7. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study

Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg (...) technology The study compared the use of esomeprazole 20 mg "on-demand"(Nexium; AstraZeneca) versus continuous (over a 6-month period) treatment with lansoprazole 15 mg once daily (Zoton Capsules; Wyeth). Esomeprazole is the s-isomer of omeprazole, a proton-pump inhibitor (PPI) licensed for on-demand use in patients with endoscopy-negative gastro-oesophageal reflux disease (GERD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with heartburn as

NHS Economic Evaluation Database.2004

8. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. 12087138 2002 06 27 2002 07 02 2013 11 21 1533-4406 346 26 2002 Jun 27 The New England journal of medicine N. Engl. J. Med. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. 2033-8 The role of gastric acid suppression in preventing the recurrence of ulcer complications after the eradication of Helicobacter pylori infection (...) in patients taking long-term low-dose aspirin is uncertain. We enrolled 123 patients who had ulcer complications after using low-dose aspirin continuously for more than one month and who had H. pylori infection. After the ulcers had healed and the H. pylori infection was eradicated, the patients were randomly assigned to treatment with 30 mg of lansoprazole daily or placebo, in addition to 100 mg of aspirin daily, for 12 months. The primary end point was the recurrence of ulcer complications. During

NEJM2002

9. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

DARE.2001

10. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis

Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis Bazzoli F, Pozzato P, Zagari M, Fossi S, Ricciardiello L, Nicolini G, Berretti D, De Luca L Authors' objectives To assess the efficacy of lansoprazole in eradicating Helicobacter pylori and healing peptic ulcers. Searching The authors searched MEDLINE and also scanned (...) the bibliographies of articles for additional relevant studies (search terms not stated). Only full-text published articles (1993 to 1996) were included although five published abstracts were included for the triple- therapy comparison of lansoprazole versus another proton pump inhibitor (PPI). Only English language studies were included. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs). Specific interventions included in the review Comparisons of: 1

DARE.1998

11. Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview.

Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Manzionna G, Pace F, Bianchi Porro G Authors' objectives To re-evaluate the short- and long-term data regarding the treatment (...) of reflux oesophagitis with the newly developed proton-pump inhibitor lansoprazole, compared with other acid suppressant drugs. Searching The literature was searched both manually and electronically (MEDLINE). Only articles published in the English language between 1991 and 1996 were considered. Study selection Study designs of evaluations included in the review Randomised, controlled clinical studies were included. Specific interventions included in the review Lansoprazole (15, 30 or 60 mg/day

DARE.1997

12. Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis

Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis Tunis S R, Sheinhait I A, Schmid C H, Bishop D J, Ross S D Authors' objectives To compare the gastric ulcer healing rates of lansoprazole with histamine2-receptor antagonists (H2RAs). Searching (...) MEDLINE (1966 - 16 January 1996) including all languages, using the subject heading 'stomach ulcer' and text terms 'lansoprazole', 'lanzor', 'ogast', 'takepron', 'Prevacid', 'AG-1749', and 'EN-123065'. In addition, Current Contents was searched weekly, and bibliographies were handsearched. Unpublished trials were obtained from the drug's manufacturer. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) comparing lansoprazole with a H2RA, recruiting

DARE.1997

13. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer

Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Poynard T, Lemaire M, Agostini H Authors' objectives To compare the clinical efficacy (...) of lansoprazole with the efficacies of ranitidine and famotidine. Searching The trials were identified using a MEDLINE search, a review of gastroenterology journals and from the files of two pharmaceutical companies (Houde and Takeda). Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Lansoprazole at the usual dose of 30 mg compared with famotidine (4 0mg) or ranitidine (300 mg). Participants

DARE.1995